106 related articles for article (PubMed ID: 36457063)
1. Targeting CD33+ acute myeloid leukemia with GLK-33, a lintuzumab-auristatin conjugate with a wide therapeutic window.
Satomaa T; Pynnönen H; Aitio O; Hiltunen JO; Pitkänen V; Lähteenmäki T; Kotiranta T; Heiskanen A; Hänninen AL; Niemelä R; Helin J; Kuusanmaki H; Vänttinen I; Rathod R; Nieminen AI; Yatkin E; Heckman CA; Kontro M; Saarinen J
Mol Cancer Ther; 2024 Apr; ():. PubMed ID: 38561023
[TBL] [Abstract][Full Text] [Related]
2. XPO1 inhibition displays anti-leukemia efficacy against DNMT3A-mutant acute myeloid leukemia via downregulating glutathione pathway.
Cai X; Liu Y; Li H; Que Y; Xiao M; Wang Y; Wang X; Li D
Ann Hematol; 2024 Mar; ():. PubMed ID: 38519605
[TBL] [Abstract][Full Text] [Related]
3. "Rich arginine and strong positive charge" antimicrobial protein protamine: From its action on cell membranes to inhibition of bacterial vital functions.
Ookubo M; Tashiro Y; Asano K; Kamei Y; Tanaka Y; Honda T; Yokoyama T; Honda M
Biochim Biophys Acta Biomembr; 2024 Apr; 1866(5):184323. PubMed ID: 38614236
[TBL] [Abstract][Full Text] [Related]
4. Phase separation-competent FBL promotes early pre-rRNA processing and translation in acute myeloid leukaemia.
Yang L; Zhang Z; Jiang P; Kong D; Yu Z; Shi D; Han Y; Chen E; Zheng W; Sun J; Zhao Y; Luo Y; Shi J; Yao H; Huang H; Qian P
Nat Cell Biol; 2024 May; ():. PubMed ID: 38745030
[TBL] [Abstract][Full Text] [Related]
5. Targeted Therapies and Druggable Genetic Anomalies in Acute Myeloid Leukemia: From Diagnostic Tools to Therapeutic Interventions.
Lanza F; Bazarbachi A
Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572925
[TBL] [Abstract][Full Text] [Related]
6. miR-21 Responsive Nanocarrier Targeting Ovarian Cancer Cells.
Han L; Song T; Wang X; Luo Y; Gu C; Li X; Wen J; Wen Z; Shi X
Comput Struct Biotechnol J; 2024 Dec; 24():196-204. PubMed ID: 38495121
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for bladder neck contracture after transurethral resection of the prostate.
Goßler C; Pfänder F; Haas M; Mayr R; Gierth M; Burger M; Rosenhammer B; Breyer J
Prostate; 2023 Aug; 83(11):1020-1027. PubMed ID: 37089004
[TBL] [Abstract][Full Text] [Related]
8. An Update on the Clinical Evaluation of Antibody-Based Therapeutics in Acute Myeloid Leukemia.
Venugopal S; Daver N; Ravandi F
Curr Hematol Malig Rep; 2021 Feb; 16(1):89-96. PubMed ID: 33630233
[TBL] [Abstract][Full Text] [Related]
9. [What is recommended in the treatment of acute myeloid leukemia?].
Thol F
Internist (Berl); 2019 Dec; 60(12):1240-1250. PubMed ID: 31690995
[TBL] [Abstract][Full Text] [Related]
10. Electrostatic anti-CD33-antibody-protamine nanocarriers as platform for a targeted treatment of acute myeloid leukemia.
Bäumer N; Scheller A; Wittmann L; Faust A; Apel M; Nimmagadda SC; Geyer C; Grunert K; Kellmann N; Peipp M; Kailayangiri S; Gutierrez Suburu ME; Strassert CA; Schenk M; Greune L; Rüter C; Dersch P; Hartmann W; Rossig C; Neri D; Müller-Tidow C; Schwöppe C; Schliemann C; Khandanpour C; Lenz G; Berdel WE; Bäumer S
J Hematol Oncol; 2022 Dec; 15(1):171. PubMed ID: 36457063
[TBL] [Abstract][Full Text] [Related]
11. Preclinical efficacy for a novel tyrosine kinase inhibitor, ArQule 531 against acute myeloid leukemia.
Elgamal OA; Mehmood A; Jeon JY; Carmichael B; Lehman A; Orwick SJ; Truxall J; Goettl VM; Wasmuth R; Tran M; Mitchell S; Lapalombella R; Eathiraj S; Schwartz B; Stegmaier K; Baker SD; Hertlein E; Byrd JC
J Hematol Oncol; 2020 Jan; 13(1):8. PubMed ID: 31992353
[TBL] [Abstract][Full Text] [Related]
12. Targeting BTK for the treatment of FLT3-ITD mutated acute myeloid leukemia.
Pillinger G; Abdul-Aziz A; Zaitseva L; Lawes M; MacEwan DJ; Bowles KM; Rushworth SA
Sci Rep; 2015 Aug; 5():12949. PubMed ID: 26292723
[TBL] [Abstract][Full Text] [Related]
13. Targeted siRNA nanocarrier: a platform technology for cancer treatment.
Bäumer N; Tiemann J; Scheller A; Meyer T; Wittmann L; Suburu MEG; Greune L; Peipp M; Kellmann N; Gumnior A; Brand C; Hartmann W; Rossig C; Müller-Tidow C; Neri D; Strassert CA; Rüter C; Dersch P; Lenz G; Koeffler HP; Berdel WE; Bäumer S
Oncogene; 2022 Apr; 41(15):2210-2224. PubMed ID: 35220407
[TBL] [Abstract][Full Text] [Related]
14. Tumor-Cell-Specific Targeting of Ibrutinib: Introducing Electrostatic Antibody-Inhibitor Conjugates (AiCs).
Faust A; Bäumer N; Schlütermann A; Becht M; Greune L; Geyer C; Rüter C; Margeta R; Wittmann L; Dersch P; Lenz G; Berdel WE; Bäumer S
Angew Chem Int Ed Engl; 2022 Jan; 61(1):e202109769. PubMed ID: 34725904
[TBL] [Abstract][Full Text] [Related]
15. Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia.
Rushworth SA; Murray MY; Zaitseva L; Bowles KM; MacEwan DJ
Blood; 2014 Feb; 123(8):1229-38. PubMed ID: 24307721
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
